<DOC>
	<DOCNO>NCT02296775</DOCNO>
	<brief_summary>This study compare plasma pharmacokinetic profile change disease activity score patient active rheumatoid arthritis follow treatment two 1000 mg dose DRL_RI one two source rituximab ( Rituxan® MabThera® ) . Patients also monitor safety , B cell depletion recovery , development immune response administer study drug</brief_summary>
	<brief_title>Comparative Pharmacokinetic , Pharmacodynamic , Safety Efficacy Study Three Anti-CD20 Monoclonal Antibodies Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Male female patient , 18 65 year age 2 . Diagnosis RA , accord ACR criterion ( 1987 ) , least 6 month duration 3 . At randomization , tender joint count ≥ 6 swollen joint count ≥ 6 4 . Evidence least moderate disease activity 5 . Patients receive oral parenteral MTX dose 15 25 mg per week give alone 10 25 mg per week combination additional nonbiologic DMARD ( ) least 6 month stable dose least 3 month 6 . Patients must stable dose folic acid equivalent ( ≥5 mg per week ) 7 . Chest Xray suggestive lung infection include pulmonary tuberculosis ( TB ) 8 . Contraception require per protocol 1 . Prior therapy Rituximab , abatacept , tocilizumab , anakinra agent/antibody target CD20 , CD19 B cell Tumor necrosis factor ( TNF ) alfa antagonists biologic DMARDs Other prior concurrent therapy may also exclude 2 . Any clinically relevant abnormality detect screen history , physical examination , clinical laboratory , chest Xray , electrocardiogram ( ECG ) , value consistent RA 3 . Evidence active , suspect inadequately treat TB 4 . Positive serological test hepatitis C virus antibody , hepatitis B surface antigen , hepatitis B core antibody , human immunodeficiency virus 5 . History cardiovascular disease , history stroke , uncontrolled hypertension 6 . History lymphoproliferative disease organ allograft 7 . History cancer ( except situ cancer , excise , limited stage , curatively treat cancer sign disease &gt; 5 year ) 8 . History allergy ( medication history ) compound use study 9 . Pregnant lactate woman woman plan become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>